New developments in antitumor anthracyclines

Pharmacology and Therapeutics

Volumn 76, Issue 1-3, 1997, Pages 117-124

  Arcamone, Federico ^a   Animati, Fabio ^a   Capranico, Giovanni ^b   Lombardi, Paolo ^a   Pratesi, Graziella ^b   Manzini, Stefano ^a   Supino, Rosanna ^b   Zunino, Franco ^b  

^a Menarini Ricerche SpA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anthracyclines; Anticancer; Disaccharide; DNA binding drugs; MEN 10755; Topoisomerase II

Indexed keywords

7 O (4' O ALPHA LEVO DAUNOSAMINYL 2' DEOXY ALPHA LEVO FUCOSYL) 4 DEMETHOXY ADRIAMYCINONE; ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; IDARUBICIN DERIVATIVE; MEN 10746; SABARUBICIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CHEMICAL MODIFICATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0031277586     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)00096-X     Document Type: Review

References (35)

1. Animati, F., Arcamone, F., Bigioni, M., Berettoni, M., Cipollone, A., Franciotti, M., Lombardi, P., Pratesi, G., Supino, R. and Zunino, F. (1996a) Novel anthracycline disaccharides: effect of the orientation of the second sugar residue on antitumor activity. Ann. Oncol. 7 (Suppl. 1): 109.
2. Animati, F., Arcamone, F., Bigioni, M., Capranico, G., Caserini, C., De Cesare, M., Lombardi P., Pratesi, G., Salvatore, C., Supino, R. and Zunino, F. (1996b) Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochetnistry and conformation. Mol. Pharmacol. 50: 603-609.
3. Animati, F., Berettoni, M., Cipollone, A., Franciotti, M., Lombardi, P., Monteagudo, E. and Arcamone, F. (1996c) New anthracycline disaccharides. Synthesis of L-daunosaminyl-α(1-4)-2-deoxy-L-rhamnosyl and of L-daunosaminyl-α(1-4)-2-deoxy-L-fucosyl daunorubicin analogues. J. Chem. Soc. Perkin. Trans. 1: 1327-1329.
4. Arcamone, F. (1981) Doxorubicin, anticancer antibiotics. In: Medicinal Chemistry Series, pp. 1-369, de Stevens, G. (ed.) Academic Press, New York.
5. Arcamone, F., Franceschi, G., Penco, S. and Selva, A. (1969) Adriamycin (14-hydroxydaunorubicin) an antitumor antibiotic. Tetrahedron Lett. 10: 1007-1010.
6. Arcamone, F., Animati, F., Berettoni, M., Bigioni, M., Capranico, G., Casazza, A. M., Caserini, C., Cipollone, A., De Cesare, M., Franciotti, M., Lombardi, P., Madami, A., Manzini, S., Monteagudo, E., Polizzi, D., Pratesi, G., Righetti, S. C., Salvatore, C., Supino, R. and Zunino, F. (1997) A doxorubicin disaccharide analog: apoptosis-related improvement of efficacy in vivo. J. Natl. Cancer Inst., in press.
7. Boivin, J., Monneret, C. and Païs, M. (1981) Approche de la synthèse d'anthracyclines oligosaccharidiques. Hemisynthèse de la 4′-O-(2-desoxy-L-fucosyl) daunorubicin. Tetrahedron 37: 4219-4228.
8. Bonadonna, G., Gianni, L., Santoro, A., Bonfante, V., Bidoli, P., Casali, P., Demicheli, R. and Valagussa, P. (1993) Drugs ten years later: epirubicin. Ann. Oncol. 4: 359-369.
9. Brockmann, H. (1963) Anthracyclinone und Anthracycline (Rhodomycinone, Pyrromycinone und lhre Glycoside). In: Fortschritte der Chemie Organischer Naturstoffe, Vol. 21, pp. 121-182, Zeichmeister, L. (ed.) Springer, Vienna.
10. Capranico, G. and Zunino, F. (1995) Antitumor inhibitors of DNA topoisomerases. Curr. Pharm. Design 1: 1-14.
11. Capranico, G., De Isabella, P., Penco, S., Tinelli, S. and Zunico, F. (1989) Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells. Cancer Res. 49: 2022-2027.
12. Capranico, G., Zunino, F., Kohn, K. W. and Pommier, Y. (1990) Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV 40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 29: 562-569.
13. Capranico, G., Supino, R., Binaschi, M., Capolongo, L., Grandi, M., Suarato, A. and Zunino, F. (1994) Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome drug resistance. Mol. Pharmacol. 45: 908-915.
14. Capranico, G., Butelli, E. and Zunino, F. (1995) Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety. Cancer Res. 55: 312-317.
15. Cassinelli, G., Configliacchi, E., Penco, S., Rivola, G., Arcamone, F., Pacciarini, A. and Ferrari, L. (1984) Separation, characterization, and analysis of epirubicin(4′-epidoxorubicin) and its metabolites from human urine. Drug Metab. Dispos. 12: 506-510.
16. Cersosimo, R. J. (1992) Idarubicin: an anthracycline antineoplastic agent. Clin. Pharmacol. 11: 152-167.
17. Di Marco, A. and Arcamone, F. (1974) DNA complexing antibiotics: daunomycin, adriamycin and their derivatives Arzneimittelforschung 25: 368-375.
18. Di Marco, A., Casazza, A. M., Gambetta, R., Supino, R. and Zunino, F. (1976) Relationship between activity and aminosugar stereochemistry in daunorubicin and adriamycin derivatives. Cancer Res. 36: 1062-1966.
19. El Khadem, H. S. and Matsuura D. (1982) Synthesis of 7-(3-amino-2,3,6,-trideoxy-4-O-(2,6-dideoxy-α-L-lyxo-hexopyranosyl)-α-L-lyxo-hexo pyranosyl) daunomycinone. Carbohydr. Res. 101: C1-C4.
20. Geran, R. I., Greenberg, N. H., Mcdonald, M. M., Schumacher, A. M. and Abbot, B. G. (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep. Part 33; -88.
21. Gigli, M., Rasoanaivo, T. W., Millot, J.-M., Jeannesson, P., Rizzo, V., Jardillier, J.-C., Arcamone, F. and Manfait, M. (1989) Correlation between growth inhibition and intranuclear coxorubicin and 4′-deoxy-4′-iododoxorubicin quantitated in living K562 cells by microspectrofluorometry. Cancer Res. 49: 560-564.
22. Gresh, N., Pullman, B., Arcamone, F., Menozzi, M. and Tonani, R. (1988) Joint experimental and theorethical investigation of the comparative DNA binding affinities of intercalating anthracycline derivatives. Mol. Pharmacol. 35: 251-256.
23. Grimm, A., Madduri, K., Ali, A. and Hutchinson, C. R. (1994) Characterization of the Streptomyces peucetius ATCC 29050 genes encoding doxorubicin polyketide synthase. Gene 151: 1-10.
24. Horton, D., Priebe, W., Sznaidman, M. L. and Varela, O. (1993) Synthesis and antiturnor activity of anthracycline disaccharide glycosides containing daunosamine. J. Antibiot. 46: 1720-1730.
25. Lombardi, P., Animati, F., Cipollone, A., Giannini, G., Monteagudo, E. and Arcamone, F. (1995) Synthesis and conformational preference of novel 8-fluoroanthracyclines. Acta Biochim. Pol. 42: 433-444.
26. Monteagudo, E., Madami, A., Animati, F., Lombardi, P. and Arcamone, F. (1997) Conformational analysis of 4-demethoxy-7-O-[2,6-dideoxy-4-O-(2,3,6-trideoxy-3-amino-α-L-lyxo-hexopyranosyl)-α-L-lyxo-hexo pyranosyl] adriamycinone, the first doxorubicin disaccharide analogue to be reported. Carbohydr. Res. 300: 11-16.
27. Moore, M. H., Hunter, W. N., Langlois d'Estanoit, B. and Kennard, O. (1989) DNA-drug interactions: the crystal structure of d(CGATCG) complexed with daunomycin. J. Mol. Biol. 206: 693-705.
28. Pasqui, F., Canfarini, F., Giolitti, A., Guidi, A., Pestellini, V. and Arcamone, F. (1996) Synthesis of ring A fluorinated anthracyclines. Tetrahedron 52: 185-198.
29. Penco, S., Angelucci, F., Ballabio, M., Barchielli, G., Suarato, A., Vanotti, E., Vogevani, A. and Arcamone, F. (1984) Synthesis and ring A conformation of new anthracyclines. Heterocycles 21: 21-27.
30. Pommier, Y. (1997) DNA topoisomerase II inhibitors. In: Cancer Therapeutics, Experimental and Clinical Agents, pp. 153-174, Techter, B. A. (ed.) Humana Press, Totowa.
31. Pratesi, G., Animati, F., Arcamone, F., Berettoni, M., Bigioni, M., Cipollone, A., Franciotti, M., Lombardi, P., Supino, R. and Zunino, F. (1996a) Antitumor activity of [L-daunosaminyl-α-(1-4)-2-deoxy-α-L-fucosyl]-4-demethoxy-adriamycinone (MEN 10755) in a panel of human tumor xenografts naturally resistant to doxorubicin. Proc. Am. Assoc. Cancer Res. 37: 394.
32. Pratesi, G., Bigioni, M., De Casare, M., Supino, R., Zunino F., Animati, F., Arcamone, F., Berettoni, M., Cipollone, A., Franciotti, M. and Lombardi, P. (1996b) Pharmacological properties of novel anthracycline aminodisaccharide in human lung and gynecological cancer. Preclinical studies. Ann. Oncol. 7 (Suppl. 1): 41.
33. Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D. and Liu, L. F. (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466-468.
34. Wang, A. H.-J., Ughetto, G., Quigley, G. J. and Rich, A. (1987) Interactions between an anthracycline antibiotic and DNA: molecular structure of daunomycin complex to d(CpGpTpApCpGp) at 1.2 Å resolution. Biochemistry 26: 1152-1163.
35. Weiss, R. B. (1992) The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19: 670-686.